Lucinda Billingham

Accepting PhD Students

PhD projects

Lucinda Billingham is Professor of Biostatistics within the Institute of Cancer and Genomic Sciences at the University of Birmingham. She has worked for over twenty years as a Biostatistician at their Cancer Research UK Clinical Trials Unit and is now Director of Statistics for the Unit working with a large team of Biostatisticians on an extensive portfolio of early and late phase trials. Lucinda has a special interest in lung cancer and sarcoma research and is the Chief Biostatistician for the National Lung Matrix Trial.As well as her PhD research on statistical methods for the simultaneous analysis of quality of life and survival data, other key areas of expertise include application of Bayesian methods in trials, design and analysis of trials in rare cancers, early phase trial design and statistical methodology for biomarker discovery, validation and evaluation for stratified medicine.
Professor Billingham is happy to supervise doctoral researchers working in her areas of interest.

Research activity per year

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

SDG 3 Good Health and Well-being
SDG 14 Life Below Water

Fingerprint

Dive into the research topics where Lucinda Billingham is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

124 Article
5 Abstract
3 Poster
3 Letter
More

Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial
Vormoor, B., Savage, J., Kristunas, C., Johnson, S., Blanco, M. N. F., Shenton, G., Lancaster, D., Castleton, A., Fielding, A. K., Latif, A.-L., Morley, N., Strullu, M., Tuckuviene, R., Kearns, P., Jennings, C., Barnett, S., Veal, G. J., Irving, J., Billingham, L. & Menne, T. & 1 others, Vormoor, J., Jun 2026, In: EJC Paediatric Oncology. 7, 10 p., 100489.
Research output: Contribution to journal › Article › peer-review

Open Access
File
17 Downloads (Pure)
SARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study
Brugha, R., Kirkham, A., Bate, J., Burke, G. A. A., Hughes, A., Magwaro, S., Pope, A. M., Beesley, R., Lax, S., Kelly, E., Greenland, M., Minassian, A. M., Liu, X., Billingham, L., McInnes, I., Goodyear, C. S., Kearns, P., Wedderburn, L. R. & OCTAVE-Minor Collaborative Group, Feb 2026, In: The Journal of pediatrics. 289, 12 p., 114873.
Research output: Contribution to journal › Article › peer-review

Open Access
File
25 Downloads (Pure)
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
Middleton, G., Robbins, H. L., Fletcher, P., Savage, J., Mehmi, M., Summers, Y., Greystoke, A., Steele, N., Popat, S., Jain, P., Spicer, J., Cave, J., Shaw, P., Gilligan, D., Power, D., Fennell, D., Bajracharya, M., Mcbride, D. J., Maheswari, U. & Frankell, A. M. & 3 others, Swanton, C., Beggs, A. D. & Billingham, L., 11 Mar 2025, In: npj Precision Oncology. 9, 1, 11 p., 67.
Research output: Contribution to journal › Article › peer-review

Open Access
File
89 Downloads (Pure)
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1
Middleton, G., Gaskell, C., Savage, J., Bridgewater, J., Ross, P., Saunders, M., Palmer, D., Plummer, R., Clive, S., Coyle, V., Thomas, A., Cunningham, D., Taniere, P. & Billingham, L., 17 Dec 2025, In: Journal for ImmunoTherapy of Cancer. 13, 12, 13 p., e012749.
Research output: Contribution to journal › Article › peer-review

Open Access
File
4 Downloads (Pure)
Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial
Young, R. J., Kirkham, A., Savage, J., Gaskell, C., Johnson, S., Dockrell, D. H., Bower, M., Westwell, S., Bowman, C., Leahy, M., Woll, P. & Billingham, L., 19 Mar 2025, In: BMC Cancer. 25, 1, 505.
Research output: Contribution to journal › Article › peer-review

Open Access
File
41 Downloads (Pure)

26 Active
42 Finished

Rethinking outcomes and statistical analyses for paediatric cancer trials
Kirton, L. (Co-Investigator), Gatz, S. (Co-Investigator), Billingham, L. (Co-Investigator) & Gates, S. (Principal Investigator)
Medical Research Council
1/11/25 → 30/04/28
Project: Research
Glo-BNHL: BMS Collaboration: A Global Study of Novel Agents in Relapsed and Refractory B-Non Hodgkin Lymphoma
Billingham, L. (Researcher), Maycock, S. (Researcher), Burke, A. (Principal Investigator) & Lawson, A. (Co-Investigator)
Bristol Myers Squibb Pharmaceuticals
1/05/25 → 31/10/29
Project: Industry
Thrombo-STOP: Apixaban thromboprophylaxis to prevent venous thromboembolism in ambulatory lung cancer patients undergoing systemic anticancer treatment
Jowett, S. (Co-Investigator), Billingham, L. (Co-Investigator), Ignatowicz, A. (Co-Investigator), Newnham, M. (Principal Investigator), Turner, A. (Co-Investigator), Pirrie, S. (Co-Investigator) & Middleton, G. (Co-Investigator)
NIHR
1/03/25 → 28/02/30
Project: Other Government Departments
LifeArc Translational Rare Disease Centre RD-TAP
Calvert, M. (Co-Investigator), Blackburn, S. (Co-Investigator), Billingham, L. (Co-Investigator), Harper, L. (Co-Investigator), Kearns, P. (Co-Investigator), Gates, S. (Co-Investigator), Aiyegbusi, L. (Co-Investigator), Trivedi, P. (Co-Investigator), Gkoutos, G. (Co-Investigator), Homer, V. (Co-Investigator), Barrett, T. (Principal Investigator), Retzer, A. (Co-Investigator) & Higgs, M. (Co-Investigator)
LifeArc
1/09/24 → 31/08/29
Project: Research
CRUK CRCTU Core Funding
Fisher, B. (Co-Investigator), Billingham, L. (Researcher), Bach, S. (Researcher), Kearns, P. (Co-Investigator), Pratt, G. (Researcher), Bowden, S. (Principal Investigator), Rea, D. (Researcher), Middleton, G. (Co-Investigator) & Gates, S. (Researcher)
Cancer Research UK
1/10/23 → 30/09/28
Project: Research

23 Conference, workshop or symposium
18 Guest lecture or Invited talk
5 Membership of working group or committee
1 Advisory role
More
- 1 Member of an organisation

A Phase II Clinical Trial with Efficacy and Toxicity Outcomes and Baseline Covariates
Brock, K. (Speaker), Billingham, L. (Contributor), Middleton, G. (Contributor) & Yap, C. (Contributor)
2 Jul 2018
Activity: Academic and Industrial events › Conference, workshop or symposium
Implementing more novel designs in cancer clinical trials: the Birmingham experience
Billingham, L. (Presenter), Yap, C. (Presenter), Brock, K. (Presenter) & Slade, D. (Presenter)
26 Mar 2018
Activity: Academic and Industrial events › Guest lecture or Invited talk
Introduction to the principles and practice of personalised medicine
Billingham, L. (Lecturer)
Mar 2018
Activity: Academic and Industrial events › Guest lecture or Invited talk
Rare Cancers - A statistician's perspective: methodology to influence clinical practice in rare cancers
Billingham, L. (Invited speaker)
27 Feb 2018
Activity: Academic and Industrial events › Conference, workshop or symposium
Role of Statistics in Early Phase Trials
Billingham, L. (Invited speaker)
30 Jan 2018
Activity: Academic and Industrial events › Conference, workshop or symposium

Behind the Scenes with the Unsung Heroes of Cancer Clinical Trials
Billingham, L.
20/05/18
1 item of Media coverage
Press/Media: Press / Media
Join the hunt for biomarkers
Billingham, L.
29/03/17
1 Media contribution
Press/Media: Press / Media

Lucinda Billingham

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial

SARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer

Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial

Rethinking outcomes and statistical analyses for paediatric cancer trials

Glo-BNHL: BMS Collaboration: A Global Study of Novel Agents in Relapsed and Refractory B-Non Hodgkin Lymphoma

Thrombo-STOP: Apixaban thromboprophylaxis to prevent venous thromboembolism in ambulatory lung cancer patients undergoing systemic anticancer treatment

LifeArc Translational Rare Disease Centre RD-TAP

CRUK CRCTU Core Funding

A Phase II Clinical Trial with Efficacy and Toxicity Outcomes and Baseline Covariates

Implementing more novel designs in cancer clinical trials: the Birmingham experience

Introduction to the principles and practice of personalised medicine

Rare Cancers - A statistician's perspective: methodology to influence clinical practice in rare cancers

Role of Statistics in Early Phase Trials

Behind the Scenes with the Unsung Heroes of Cancer Clinical Trials

Join the hunt for biomarkers

Lucinda Billingham

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Research output

Projects

Activities

Press/Media